High Levels of Protein Found in Bones and Gut May Link AS and IBD
High Levels of Protein Found in Bones and Gut May Link AS and IBD
Ankylosing Spondylitis Treatment Report
www.AnkylosingSpondylitisTreatmentReport.com
High Levels of Protein Found in Bones and Gut May Link AS and IBD
High Levels of Protein Found in Bones and Gut May Link AS and IBD
https://www.ncbi.nlm.nih.gov/pubmed/32219620?dopt=Abstract
https://link.springer.com/article/10.1007%2Fs10067-020-05032-4
TITLE:
Dynamic changes in gut microbiota under the influence of smoking and TNF-α-blocker in patients with ankylosing spondylitis.
DESCRIPTION:
Related Articles
Dynamic changes in gut microbiota under the influence of smoking and TNF-α-blocker in patients with ankylosing spondylitis.
Clin Rheumatol. 2020 Mar 26;:
Authors: Zhang F, Ma C, Zhang B, Bi L
Abstract
OBJECTIVES: This study aimed to investigate the relationship among smoking, TNF-α-blocker therapy, and the dynamic changes in gut microbiota in patients with ankylosing spondylitis (AS).
METHODS: Using a 16S rRNA sequence, 98 fecal samples of 20 AS patients collected after 0, 1, 3 and 6 months of anti-TNF-α treatment and from 20 matched health controls were examined. The variation in composition, abundance, and diversity of gut microbiota was analyzed. The dynamic effects of smoking and treatment on gut microbiota and therapeutic efficacy in AS patients were studied.
RESULTS: The increased relative abundance of microbiota in AS nonsmokers was g_Comamonas and g_Desulfovibrio, while that in AS smokers was g_Actinomyces, g_Collinsella, g_Lachnospiraceae_UCG-008, and g_Paraprevotella. The relative abundance of gut microbiota showed dynamic variation. The improvement rate of ASDAS in AS nonsmokers was higher than that in AS smokers (2.297 vs 1.736) after anti-TNF-α treatment. The β-diversity of gut microbiota in AS smokers was lower than that in AS nonsmokers and improved with treatment.
CONCLUSIONS: Both smoking and TNF-α-blocker had significant effects on the composition, relative abundance, and diversity of gut microbiota in AS patients. The AS smokers characteristically shared g_Collinsella and g_Dorea. The relative abundance of gut microbiota revealed high variability and was in dynamic fluctuation during treatment. The response of gut microbiota to anti-TNF-α treatment was found to be heterogeneous and selective. AS nonsmokers showed a greater improvement rate of ASDAS-CRP with treatment than AS smokers did. The AS smokers showed a lower β-diversity of gut microbiota, and improved after treatment.Key Points• Characterized the dynamic variation in gut microbiota in AS patients classified as smokers and nonsmokers during treatment with anti-TNF-α.• Confirmed the interaction between smoking, anti-TNF-α therapy, and gut microbiota.
PMID: 32219620 [PubMed – as supplied by publisher]
PMID:
PubMed:32219620
DATE FOUND:
03/29/20 06:18AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32219620?dopt=Abstract
https://www.spondylitis.org/About-SAA/Updates/the-role-of-the-gut-microbiome-in-ankylosing-spondylitis
The Role of the Gut Microbiome in Ankylosing Spondylitis
By Spondylitis Association of America
Altered Gut Microbiome Contributes to Inflammation in Ankylosing Spondylitis, Study Suggests
Altered Gut Microbiome Contributes to Inflammation in Ankylosing Spondylitis, Study Suggests
https://www.rheumatologyadvisor.com/home/topics/ankylosing-spondylitis/metagenomic-sequencing-reconfirms-key-role-of-gut-microbiome-in-as-pathogenesis/
Metagenomic Sequencing Reconfirms Key Role of Gut Microbiome in AS Pathogenesis
https://ard.bmj.com/content/79/1/132
Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition
https://www.sciencedirect.com/science/article/pii/S0896841119306377?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/31806420?dopt=Abstract
TITLE:
Metagenomic profiling of the pro-inflammatory gut microbiota in ankylosing spondylitis.
DESCRIPTION:
Related Articles
Metagenomic profiling of the pro-inflammatory gut microbiota in ankylosing spondylitis.
J Autoimmun. 2019 Dec 02;:102360
Authors: Zhou C, Zhao H, Xiao XY, Chen BD, Guo RJ, Wang Q, Chen H, Zhao LD, Zhang CC, Jiao YH, Ju YM, Yang HX, Fei YY, Wang L, Shen M, Li H, Wang XH, Lu X, Yang B, Liu JJ, Li J, Peng LY, Zheng WJ, Zhang CY, Zhou JX, Wu QJ, Yang YJ, Su JM, Shi Q, Wu D, Zhang W, Zhang FC, Jia HJ, Liu DP, Jie ZY, Zhang X
Abstract
OBJECTIVE: Gut dysbiosis has been reported implicated in ankylosing spondylitis (AS), a common chronic inflammatory disease mainly affects sacroiliac joints and spine. Utilizing deep sequencing on the feces of untreated AS patients, our study aimed at providing an in-depth understanding of AS gut microbiota.
METHODS: We analyzed the fecal metagenome of 85 untreated AS patients and 62 healthy controls by metagenomic shotgun sequencing, and 23 post-treatment feces of those AS patients were collected for comparison. Comparative analyses among different cohorts including AS, rheumatoid arthritis and Behcet’s disease were performed to uncover some common signatures related to inflammatory arthritis. Molecular mimicry of a microbial peptide was also demonstrated by ELISpot assay.
RESULTS: We identified AS-enriched species including Bacteroides coprophilus, Parabacteroides distasonis, Eubacterium siraeum, Acidaminococcus fermentans and Prevotella copri. Pathway analysis revealed increased oxidative phosphorylation, lipopolysaccharide biosynthesis and glycosaminoglycan degradation in AS gut microbiota. Microbial signatures of AS gut selected by random forest model showed high distinguishing accuracy. Some common signatures related to autoimmunity, such as Bacteroides fragilis and type III secretion system (T3SS), were also found. Finally, in vitro experiments demonstrated an increased amount of IFN-γ producing cells triggered by a bacterial peptide of AS-enriched species, mimicking type II collagen.
CONCLUSIONS: These findings collectively indicate that gut microbiota was perturbed in untreated AS patients with diagnostic potential, and some AS-enriched species might be triggers of autoimmunity by molecular mimicry. Additionally, different inflammatory arthritis shared some common microbial signatures.
PMID: 31806420 [PubMed – as supplied by publisher]
PMID:
PubMed:31806420
DATE FOUND:
12/07/19 06:24AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31806420?dopt=Abstract
frontiersin.org/articles/10.3389/fcimb.2019.00044/full?fbclid=IwAR09NWznWE8Mq-4qwKf7mI3csmsq9Dv9f1qspD5Jy3JCaPNwVqOcvpOFrqk
Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice
https://www.biorxiv.org/content/10.1101/517813v1.full
“therapies targeting the gut microbiome may be effective in the prevention and/or treatment of ankylosing spondylitis”
HLA alleles associated with risk of ankylosing spondylitis and rheumatoid arthritis influence the gut microbiome
Mark Asquith, Peter R. Sternes, Mary-Ellen Costello, Lisa Karstens, Sarah Diamond, Tammy M. Martin, Timothy D. Spector, Kim-Anh le Cao, James T. Rosenbaum, Matthew A. Brown
doi: https://doi.org/10.1101/517813
Now published in Arthritis & Rheumatology doi: 10.1002/art.40917
AbstractFull TextInfo/HistoryMetrics Preview PDF
ABSTRACT
Objectives HLA alleles affect susceptibility to more than 100 diseases, but the mechanisms to account for these genotype-disease associations are largely unknown. HLA-alleles strongly influence predisposition to ankylosing spondylitis (AS) and rheumatoid arthritis (RA). Both AS and RA patients have discrete intestinal and faecal microbiome signatures. Whether these changes are cause or consequence of the diseases themselves is unclear. To distinguish these possibilities, we examine the effect of HLA-B27 and HLA-DRB1 RA-risk alleles on the composition of the intestinal microbiome in healthy individuals.
Methods 568 samples from 6 intestinal sites were collected from 107 otherwise healthy unrelated subjects and stool samples from 696 twin pairs from the TwinsUK cohort. Microbiome profiling was performed using sequencing of the 16S rRNA bacterial marker gene. All patients were genotyped using the Illumina CoreExome SNP microarray, and HLA genotypes were imputed from these data.
Results Association was observed between HLA-B27 genotype, and RA-risk HLA-DRB1 alleles, and overall microbial composition (P=0.0002 and P=0.00001 respectively). These associations were replicated in the TwinsUK cohort stool samples (P=0.023 and P=0.033 respectively).
Conclusions This study shows that the changes in intestinal microbiome composition seen in AS and RA are at least partially due to effects of HLA-B27 and –DRB1 on the gut microbiome. These findings support the hypothesis that HLA alleles operate to cause or increase the risk of these diseases through interaction with the intestinal microbiome, and suggest that therapies targeting the microbiome may be effective in their prevention and/or treatment.
INTRODUCTION